{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:16Z","timestamp":1786991836106,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jclinepi.2021.12.018","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T11:16:18Z","timestamp":1639826178000},"page":"43-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-4396","authenticated-orcid":false,"given":"Ariel","family":"Izcovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-6055","authenticated-orcid":false,"given":"Fernando","family":"Tortosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-0710","authenticated-orcid":false,"given":"Gabriel","family":"Rada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Aldighieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Reveiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2021.12.018_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104371","article-title":"Prevalence and severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"127","author":"Hu","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0002","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1473-3099(20)30565-X","article-title":"The lancet infectious diseases null. The COVID-19 infodemic","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/d41586-021-01246-x","article-title":"How COVID broke the evidence pipeline","volume":"593","author":"Pearson","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0004","unstructured":"WHO international registry of clinical trials platform (ICTRP). Available at: https:\/\/www.who.int\/clinical-trials-registry-platform. Accessed June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0005","unstructured":"WHO essentials medicine list. Available at: https:\/\/list.essentialmeds.org\/medicines\/58. Accessed on June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0007","unstructured":"COVID-19 L.OVE platform (Epistemonikos Foundation). Ivermectin for COVID-19. Available at: https:\/\/app.iloveevidence.com\/loves\/5e6fdb9669c00e4ac072701d?question_domain=5b1dcd8ae611de7ae84e8f14&population=5e7fce7e3d05156b5f5e032a&intervention=5e89364e3d05155262cbab44&classification=systematic-review&studify=true). Accessed June 26, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0008","unstructured":"British ivermectin recommendation development (BIRD). Available at: https:\/\/bird-group.org. Accessed on June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0009","unstructured":"WHO. Therapeutics and COVID-19: living guideline. Available at: https:\/\/app.magicapp.org\/#\/guideline\/nBkO1E. Accessed on June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0010","unstructured":"IDSA guidelines on the treatment and management of patients with COVID-19. Available at: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/#toc-14. Accessed on June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0011","unstructured":"National COVID-19 clinical evidence task force. Caring for people with COVID-19. Available at: https:\/\/covid19evidence.net.au\/. Accessed on June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0012","unstructured":"Pan American Health Organization. Guidelines for Care of Critically Ill Adult Patients with COVID-19 in the Americas. Available at: https:\/\/iris.paho.org\/handle\/10665.2\/53895. Accessed on June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-020-01190-w","article-title":"COVID-19-related medical research: a meta-research and critical appraisal","volume":"21","author":"Raynaud","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0014","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.15585\/mmwr.mm6935a4","article-title":"Hydroxychloroquine and chloroquine prescribing patterns by provider specialty following initial reports of potential benefit for COVID-19 Treatment \u2014 United States, January\u2013June 2020","volume":"69","author":"Bull-Otterson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0016","doi-asserted-by":"crossref","first-page":"e7868","DOI":"10.5867\/medwave.2020.03.7867","article-title":"Evidence synthesis relevant to COVID-19: a protocol for multiple systematic reviews and overviews of systematic reviews","volume":"20","author":"Rada","year":"2020","journal-title":"Medwave"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0017","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Cognit Health"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0019","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE Working Group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0021","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0022","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0023","article-title":"Cluster randomised trials - ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers","author":"Chahla","year":"2021","journal-title":"Res Sq"},{"issue":"4","key":"10.1016\/j.jclinepi.2021.12.018_bib0024","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","article-title":"Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines","volume":"28","author":"Bryant","year":"2021","journal-title":"Am J Ther"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0025","unstructured":"Petkov S. Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Investigating Efficacy, Safety and Tolerability of Ivermectin HUVE-19 in Patients with Proven SARS-CoV-2 Infection (Covid-19) and Manifested Clinical Symptoms. 2021. Available at: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002091-12\/BG. Accessed June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0026","article-title":"A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness","author":"Ahmed","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0027","article-title":"Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. a controlled clinical trial","author":"Beltran Gonzalez","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0028","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12879-021-06348-5","article-title":"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial","volume":"21","author":"Vallejos","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0029","article-title":"Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 Pandemic","author":"Elgazzar","year":"2020","journal-title":"Res Sq"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial","volume":"32","author":"Chaccour","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0031","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijid.2021.04.035","article-title":"Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial","volume":"106","author":"Seet","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0032","article-title":"A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients","author":"Chowdhury","year":"2020","journal-title":"Res Sq"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0033","first-page":"002","article-title":"Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study","volume":"14","author":"Podder","year":"2020","journal-title":"IMC J Med Sci"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211013550","article-title":"Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial","volume":"49","author":"Mahmud","year":"2021","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100959","article-title":"Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial","volume":"37","author":"Krolewiecki","year":"2021","journal-title":"EclinicalMedicine"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0036","first-page":"31","article-title":"Effectiveness of Ivermectin in SARS-CoV-2\/COVID-19 Patients","volume":"9","author":"Chachar","year":"2020","journal-title":"Int J Sci"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0037","article-title":"Ivermectin as a potential treatment for mild to moderate COVID-19: a double blind randomized placebo-controlled trial","author":"Kirti","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0038","article-title":"Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial","author":"Mohan","year":"2021","journal-title":"Res Sq"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0039","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/v13060989","article-title":"Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in lebanon","volume":"13","author":"Samaha","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0040","article-title":"Efficacy of Ivermectin in COVID-19 patients with mild to moderate disease","author":"Bukhari","year":"2021","journal-title":"MedRxiv"},{"issue":"14","key":"10.1016\/j.jclinepi.2021.12.018_bib0041","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jclinepi.2021.12.018_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36106\/paripex\/4801859","article-title":"Ivermectin as adjuvant to hydroxychloroquine in patients resistent to standard treatment for SARS-CoV-2: Results of an open-label randomized clinical study","volume":"9","author":"Kishoria","year":"2020","journal-title":"PIJR"},{"issue":"10","key":"10.1016\/j.jclinepi.2021.12.018_bib0043","first-page":"27122","article-title":"Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study","volume":"43","author":"Abd-Elsalam","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0044","article-title":"Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 \u2013 A double-blind, randomized placebo-controlled trial","author":"Biber","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.29309\/TPMJ\/2021.28.05.5867","article-title":"Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19","volume":"28","author":"Faisal","year":"2021","journal-title":"TPMJ"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0046","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12879-021-06104-9","article-title":"Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients","volume":"21","author":"Okumu\u015f","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0047","first-page":"1","article-title":"Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection","volume":"8","author":"Bermejo Galan","year":"2021","journal-title":"Pathog GlobHealth"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0048","article-title":"Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq","author":"Hashim","year":"2020","journal-title":"MedRvix"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0049","article-title":"Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial [Internet]","author":"Niaee","year":"2020","journal-title":"Research Square"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0050","first-page":"hcab035","article-title":"Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos","author":"Babalola","year":"2021","journal-title":"QJM: Int J Med"},{"issue":"6","key":"10.1016\/j.jclinepi.2021.12.018_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2021.04.007","article-title":"Effect of ivermectin on COVID-19: a multicenter double-blind randomized controlled clinical trial","volume":"43","author":"Shahbaznejad","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0052","article-title":"Use of ivermectin in the treatment of Covid-19: a pilot trial","volume":"8","author":"Pott-Junior","year":"2021","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0053","first-page":"27","article-title":"Use of ivermectin as a potential chemoprophylaxis for COVID-19 in egypt: a randomised clinical trial","volume":"15","author":"Shoumann","year":"2021","journal-title":"JCDR"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0054","article-title":"A randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID- 19 in healthcare agents","author":"Chahla","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0055","unstructured":"Rada G. Ivermectin for COVID-19 (Matrix of evidence, Epistemonikos). Available at: http:\/\/www.epistemonikos.org\/matrixes\/601138e77aaac854cf94ac1f. Accessed June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0056","series-title":"Cochrane Database of Systematic Reviews","article-title":"Ivermectin for preventing and treating COVID-19","author":"Popp","year":"2021"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0057","unstructured":"COVID-NMA. Available at: https:\/\/covid-nma.com. Accessed June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0058","article-title":"Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection","author":"Hill","year":"2021","journal-title":"Res Sq"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0059","article-title":"A meta-analysis of mortality, need for ICU admission, use of mechanical ventilation and adverse effects with ivermectin use in COVID-19 Patients","author":"Karale","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00508-020-01805-8","article-title":"Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID)","volume":"133","author":"investigators","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0061","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"NEJM"},{"issue":"9","key":"10.1016\/j.jclinepi.2021.12.018_bib0062","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0063","article-title":"Convalescent plasma for COVID-19: a multicenter, randomized clinical trial","author":"Avenda\u00f1o-Sol\u00e0","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0064","doi-asserted-by":"crossref","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. NEJM 2021;384:693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0065","unstructured":"RECOVERY collaborative group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet 2021;397:2049\u20132\/59."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0066","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Horby","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0067","doi-asserted-by":"crossref","unstructured":"WHO solidarity trial consortium. repurposed antiviral drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results. NEJM 2021;384:497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0068","unstructured":"WHO. Handbook for good clinical research practice (GCP). Available at: https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/gcp1.pdf. Accessed June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0069","unstructured":"FDA. Good Clinical practice (GCP). Available at: https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/good-clinical-practice. Accessed June 27, 2021."},{"key":"10.1016\/j.jclinepi.2021.12.018_bib0070","unstructured":"ISO 14155:2011. Clinical investigation of medical devices for human subjects \u2014 Good clinical practice. Available at: https:\/\/www.iso.org\/standard\/45557.html. Accessed June 27, 2021."}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435621004224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435621004224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:22:19Z","timestamp":1760246539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435621004224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":70,"alternative-id":["S0895435621004224"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2021.12.018","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.19.21262304","asserted-by":"object"}]},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2021.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}